based on an off-the-shelf antigen presenting cell line
New class of antigen-specific cancer immunotherapy

News

PDC*line Pharma completes enrolment of four cohorts of patients in PDC-LUNG-101 phase I/II clinical trial

2023-12

PDC*line Pharma completes enrolment of four cohorts of patients
in PDC-LUNG-101 phase I/II clinical trial.

Total of 67 patients dosed in four cohorts in PDC-LUNG-101 trial with PDC*lung01 therapeutic cancer vaccine candidate for non-small cell lung

Read more about PDC*line Pharma completes enrolment of four cohorts of patients in PDC-LUNG-101 phase I/II clinical trial

NOUS RECHERCHONS UN QA ASSISTANT

2023-07

QA assistant

In relation to the activities carried out by PDC*line Pharma, the person occupying the position of QA and logistics assistant has the following responsibilities:
- Participate to the development and maintenance of the Quality

Read more about NOUS RECHERCHONS UN QA ASSISTANT

A new article with an interview of our CEO Eric Halioua published this week in the magazine PharmaBoardroom

2023-06

We are very pleased to announce the publication of a a new article with an interview of our CEO Eric Halioua published this week in the magazine PharmaBoardroom, the global platform for healthcare & life sciences executives. Eric provides updates on

Read more about A new article with an interview of our CEO Eric Halioua published this week in the magazine PharmaBoardroom

Our CEO Shares Insights on the Results from ongoing PDC-LUNG-101 clinical trial in e-Magazine PharmaShots

2023-06

Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from ongoing PDC-LUNG-101 clinical trial

We are very pleased to announce that a new article, following an interview of our CEO Eric Halioua, has been published in the

Read more about Our CEO Shares Insights on the Results from ongoing PDC-LUNG-101 clinical trial in e-Magazine PharmaShots

PDC*line Pharma will be presenting a poster in the “Therapeutic Vaccination” session of the 20th Cancer IMmunoTherapy (CIMT) annual meeting

2023-04

PDC*line Pharma will be presenting a poster in the “Therapeutic Vaccination” session of the 20th Cancer IMmunoTherapy (CIMT) annual meeting taking place from 3 to 5 May 2023, in Mainz (Germany). The poster will highlight immunological data from

Read more about PDC*line Pharma will be presenting a poster in the “Therapeutic Vaccination” session of the 20th Cancer IMmunoTherapy (CIMT) annual meeting

linkedin
twitter

PDC*line Pharma

Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in clinical development (PDC*lung) and on neoantigens (PDC*Neo). PDC*line Pharma comprises a team of highly skilled professionals based in Liège (Belgium) and Grenoble (France).

About us

A first in class Plasmacytoid Dendritic cell line, PDC*line providing unmatched advantages

Potent & effective

Induction of a strong cytotoxic immune response directed against a selection of tumour antigens

Scalable & convenient

Simple production of a large quantity of a highly qualified off-the-shelf product

Versatile & applicable to any cancers

The peptides can easily be changed to target a specific cancer type

Management Team

Eric Halioua

Laurent Levy

Dr. Joel Plumas

Claude DEDRY

Dr. Beatrice De Vos

Candidate products

Melanoma

Melanoma is the most lethal form of skin cancer, representing 2% of all newly diagnosed cancer cases (232,000 new cases and 55,000 deaths worldwide in 2012). It is also the leading cancer in terms of incidence increase (+ 10% per year) and one of the most common cancers in young adults (18-35 years).

Melanoma is often easier to detect in its early stages than most cancers. However, it is also more likely to spread (metastasize) to other parts of the body, and 16% of patients are first diagnosed at an advanced stage. Despite new treatments, prognosis for this late-stage disease is very unfavorable (5-year mortality rate of 85%).

Read more about PDC mel

Lung Cancer

Lung cancer is the most common malignancy worldwide for male patients and for both sexes combined (2.1 million new cases per year), and the third most common for female patients (after breast and colorectal cancers). Deaths from lung cancer exceed those from any other malignancy globally, with the number of lung-cancer-related deaths worldwide for 2018 estimated at 1.8 million (Globocan 2018), representing 18.4% for both sexes. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing 80% of cases.

Read more about Lung Cancer

Technology

PDC*line, our proprietary allogeneic cell line of Plasmacytoid Dendritic Cells solves the industrial limitations faced by immunotherapies based on dendritic cells currently on the market or in clinical development. Additionally PDC*line is much more potent than conventional dendritic cells to expand anti-tumor CD8+ T cells in vitro.

About our technology